PERAMALAN SEPSIS AKIBAT PROCALCITONIN TERKAIT KELUARAN HASIL KLINIS

Abstract

Sepsis is a systemic inflammatory response due to a severe infection. The systemic immune response rises after the local immune
response does not successfully eliminate the antigen. Procalcitonin (PCT) has been known as the marker for bacterial infection. The aim
of this study was to know whether PCT could be used as a predictor of clinical outcome in sepsis incidence. A prospective cohort design
was used in this study. The subjects were patients entering the Internal ward who met the inclusion and exclusion criteria and examined
for the basic data collection. For the assessment of SOFA (Sepsis-related Organ Failure Assessment) score, blood specimens were taken
for PCT examination, on the first day since the diagnosis of sepsis and on the third day. The patients were observed until the tenth day
to determine the assessment of their survival analysis. This study involved 50 subjects who fulfilled the inclusion and exclusion criteria.
The mean levels of PCT on day I and III were 5.19±5.83 ng/mL and 6.37±9.85 ng/mL, respectively. The mean levels of PCT on day I and
III in the group with increased SOFA score was 5.01±1.17 ng/mL and 3.86±1.46 ng/mL, respectively. The mean levels of PCT on day I
and III in the group without increased SOFA was 5.32±1.21 ng/mL and 4.88±2.21 ng/mL, respectively. The relative risk of increased
PCT against the poor output expressed by the increased SOFA score was 5.75. In the survival analysis, it was shown that 52% of patients
survived at day 10. In the group of non survival patients; the number of patients with increased PCT was more than that without increased
PCT. Based on this study, it can be concluded that procalcitonin could be used as a predictor for the clinical outcome in sepsis patients.